39 results
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and convenient dosing regimen with the potential for subcutaneous administration. Following the closing of the acquisition, Eliem’s strategy … ; the strategy, anticipated milestones and key inflection points of the combined company; the anticipated use of proceeds of the private placement
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
the establishment or modification of a Risk Evaluation and Mitigation Strategy (“REMS”) or a comparable foreign regulatory authority may require … the establishment or modification of a similar strategy that may, for instance, restrict distribution of TNT119 and impose burdensome implementation requirements
8-K
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of Tenet by Eliem; the anticipated benefits of the acquisition; the strategy, anticipated milestones and key inflection points of the combined company
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
for which Tenet plans to develop TNT119 and the current stage of development in each indication:
Tenet’s Strategy
Tenet’s strategy since the asset … .
The key elements of Tenet’s strategy for TNT119 include:
Advance TNT119 through clinical development for patients with SLE. Tenet is developing TNT119
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
warnings about TNT119;
the FDA may require the establishment or modification of a Risk Evaluation and Mitigation Strategy (“REMS”) or a comparable foreign … regulatory authority may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of TNT119
PREM14A
e6vugh
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
9r509j
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
xbh89ggat19miyjv5o
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
q41sz9
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
do0bdui1p 3erbl
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
b3urj6m5r
11 May 23
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
4:12pm
8-K
EX-99.2
9q4xtvjk
14 Nov 22
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
6:10am